Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1550-7416
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics ; volume:23 ; number:2 ; day:7 ; month:3 ; year:2021 ; pages:1-11 ; date:3.2021
The AAPS journal / American Association of Pharmaceutical Scientists ; 23, Heft 2 (7.3.2021), 1-11, 3.2021
- Urheber
-
Twomey, Julianne D.
Zhang, Baolin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1208/s12248-021-00574-0
- URN
-
urn:nbn:de:101:1-2021052820252357273483
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Twomey, Julianne D.
- Zhang, Baolin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
The First FDA-Approved Antibody-Drug Conjugate
Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
The First FDA-Approved Antibody-Drug Conjugate
Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
The First FDA-Approved Antibody-Drug Conjugate
Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia